arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

NEUROCRINE BIOSCIENCES INC

NBIX
$159.81 ▼ -6.22 (-3.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
69 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
81
Health
Excellent
Bullish
auto_awesome

Analytical Summary

NEUROCRINE BIOSCIENCES INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $16.2B
Dividend Yield —
Revenue Growth 41.2% ↗
Op. Margin 29.5% ↗
ROIC 6.2% ↗
FCF / Share $3.78 ↗
Trailing P/E 78.7x
Price / Book 4.2x
FCF Yield 2.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.12B
↑ +41.2% —
Net Income Profit after all expenses
$206.50M
↓ -1.4% —
Operating Margin Operating profit as % of sales
29.5%
↑ +86.8% 78th
FCF / Share Free cash flow per share
$3.78
↑ +196.5% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
81
Returns ↑
80
Cash Quality ↓
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters